Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass.

[1]  B. McCrindle,et al.  Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery. , 2010, The journal of extra-corporeal technology.

[2]  P. Fallon,et al.  Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. , 2009, Blood.

[3]  F. Szlam,et al.  A Comparison of Heparin Management Strategies in Infants Undergoing Cardiopulmonary Bypass , 2008, Anesthesia and analgesia.

[4]  P. Monagle,et al.  Developmental haemostasis , 2006, Thrombosis and Haemostasis.

[5]  F. Szlam,et al.  An Evaluation of the Effects of a Standard Heparin Dose on Thrombin Inhibition During Cardiopulmonary Bypass in Neonates , 2005, Anesthesia and analgesia.

[6]  B. Giroir,et al.  Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. , 2004, The New England journal of medicine.

[7]  M. Appelblad,et al.  Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec® ACT and Hemochron® Jr apparatus , 2004, Perfusion.

[8]  W. Kuebler,et al.  Heparin-Level-Based Anticoagulation Management During Cardiopulmonary Bypass: A Pilot Investigation on the Effects of a Half-Dose Aprotinin Protocol on Postoperative Blood Loss and Hemostatic Activation and Inflammatory Response , 2004, Anesthesia and analgesia.

[9]  Nancy E. Marsh,et al.  Heparin monitoring during cardiac surgery. Part 2: calculating the overestimation of heparin by the activated clotting time , 2003, Perfusion.

[10]  M. Ray,et al.  Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time , 2003, Perfusion.

[11]  R. Hetzer,et al.  Hemostatic Activation and Inflammatory Response during Cardiopulmonary Bypass: Impact of Heparin Management , 2002, Anesthesiology.

[12]  G. von Bernuth,et al.  Cytokine balance in infants undergoing cardiac operation. , 2002, The Annals of thoracic surgery.

[13]  C. Ludlam,et al.  Individualized heparin and protamine management in infants and children undergoing cardiac operations. , 2001, The Annals of thoracic surgery.

[14]  G. Gravlee,et al.  Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. , 1999, Anesthesiology.

[15]  J. Jaggers,et al.  Infant cardiopulmonary bypass: a procoagulant state. , 1999, The Annals of thoracic surgery.

[16]  S. Bratton,et al.  Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. , 1999, Anesthesia and analgesia.

[17]  M. Elliott.  Modified ultrafiltration and open heart surgery in children , 1999, Paediatric anaesthesia.

[18]  S. Bratton,et al.  Association between age and blood loss in children undergoing open heart operations. , 1998, The Annals of thoracic surgery.

[19]  G. Despotis,et al.  A comparison between continuous infusion versus standard bolus administration of heparin based on monitoring in cardiac surgery , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  W. Williams,et al.  Coagulation and Fibrinolytic Profile of Paediatric Patients Undergoing Cardiopulmonary Bypass , 1997, Thrombosis and Haemostasis.

[21]  E. Spitznagel,et al.  More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT , 1996, Thrombosis and Haemostasis.

[22]  G. Rivard,et al.  Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. , 1996, The Annals of thoracic surgery.

[23]  J. Shayevitz,et al.  Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients. , 1996, Journal of cardiothoracic and vascular anesthesia.

[24]  G. Despotis,et al.  Aprotinin Prolongs Activated and Nonactivated Whole Blood Clotting Time and Potentiates the Effect of Heparin In Vitro , 1996, Anesthesia and analgesia.

[25]  C. Greenberg,et al.  Characterization of Prothrombin Activation during Cardiac Surgery by Hemostatic Molecular Markers , 1994, Anesthesiology.

[26]  W. Williams,et al.  Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[27]  V. Olshove,et al.  Heparin dose response in pediatric cardiopulmonary bypass , 1994 .

[28]  W. Williams,et al.  Heparin Therapy during Cardiopulmonary Bypass in Children Requires Ongoing Quality Control , 1993, Thrombosis and Haemostasis.

[29]  H. Philippou,et al.  Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. , 1993, Blood.

[30]  F. Ofosu,et al.  Maturation of the hemostatic system during childhood. , 1992, Blood.

[31]  P. Hickey,et al.  Coagulation defects in neonates during cardiopulmonary bypass. , 1992, The Annals of thoracic surgery.

[32]  Carolyn H. Fotouhi,et al.  Comparison study of the Hepcon System Four and the Hemostasis Management System , 1991, Perfusion.

[33]  C. Lake.  Pediatric Cardiac Anesthesia , 1988 .

[34]  P. Powers,et al.  Development of the human coagulation system in the full-term infant. , 1987, Blood.

[35]  F. Spencer,et al.  Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. , 1981, Annals of surgery.

[36]  D. Benson,et al.  Control of heparin therapy in open-heart surgery. , 1974, The Journal of thoracic and cardiovascular surgery.

[37]  S. Epstein,et al.  Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood coagulation time, and an automated coagulation time. , 1973, American journal of clinical pathology.

[38]  E. B. Tuohy.  Progress in anesthesiology. , 1950, Postgraduate medicine.